Japan Approves First Humira Biosimilar
Mylan Will Market Fujifilm Kyowa Kirin’s Adalimumab Rival In Japan
Executive Summary
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.